突触小体相关蛋白-25在神经退行性疾病中的研究进展

Recent advance in role of synaptosomal-associated protein-25 in neurodegenerative diseases

突触功能障碍是神经退行性疾病中神经退行性变的重要病理机制之一,检测突触蛋白生物标志物在判定疾病进展及监测疾病修饰药物的临床疗效中具有重要价值。突触小体相关蛋白-25是突触前质膜蛋白,能准确反映神经退行性疾病中发生的突触损伤,是目前十分有前景的评估突触功能的生物标志物。本文现围绕突触小体相关蛋白-25的基本特征、功能及其在阿尔茨海默病、帕金森病、路易体相关痴呆等神经退行性疾病中的研究进展进行综述,以期为在临床前阶段早期识别高危患者的病理改变、监测患者病情进展以及开发新的治疗靶点提供参考依据。

Synaptic dysfunction is one of the important pathophysiological mechanisms of neurodegeneration in neurodegenerative diseases,and detection of synaptic protein biomarkers is of great value in determining disease progression and clinically monitoring the efficacy of disease-modifying drugs.Synaptosome-associated protein-25 is a presynaptic plasma membrane protein that can reliably reflect synaptic damage in neurodegenerative diseases,and may be the most promising biomarker to evaluate synaptic function.This review focuses on the basic characteristics and functions of synaptosome-related protein-25 and its research progress in neurodegenerative diseases such as Alzheimer's disease,Parkinson's disease and Lewy body dementias,in order to identify pathological changes and early diagnosis of high-risk patients early at preclinical stage,and seek opportunities for disease monitoring and new therapeutic targets.